METHODS FOR THE IDENTIFICATION OF POLYPEPTIDE ANTIGENS ASSOCIATED WITH DISORDERS INVOLVING ABERRANT CELL PROLIFERATION AND COMPOSITIONS USEFUL FOR THE TREATMENT OF SUCH DISORDERS
    10.
    发明申请
    METHODS FOR THE IDENTIFICATION OF POLYPEPTIDE ANTIGENS ASSOCIATED WITH DISORDERS INVOLVING ABERRANT CELL PROLIFERATION AND COMPOSITIONS USEFUL FOR THE TREATMENT OF SUCH DISORDERS 审中-公开
    鉴定涉及涉及细胞增殖的疾病的多肽抗原的方法和用于治疗这种疾病的组合物

    公开(公告)号:US20090304689A1

    公开(公告)日:2009-12-10

    申请号:US12364202

    申请日:2009-02-02

    摘要: Methods and compositions for the development of effective cancer therapies using mitotic inhibitors which have limited general toxicity to normal, non-cancerous cells and tissues are provided. The methods and compositions utilize cytotoxic compounds comprised of a cell-binding agent (e.g., antibodies) conjugated to an anti-mitotic compound (e.g., maytansinoids). The invention further provides antibodies which are substantially incapable of inducing antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC), thereby ensuring that the therapeutic effect is mediated primarily by the anti-mitotic component of the cytotoxic compound, rather than by indirect cell killing via ADCC and/or CDC. The antibodies of the invention further are capable of differentiating between polypeptide antigens which are more highly expressed on proliferating cancer cells as compared to proliferating non-cancer cells.

    摘要翻译: 提供了使用对正常非癌细胞和组织具有有限的一般毒性的有丝分裂抑制剂来开发有效的癌症疗法的方法和组合物。 所述方法和组合物使用由与抗有丝分裂化合物(例如美登木素生物碱)缀合的细胞结合剂(例如抗体)组成的细胞毒性化合物。 本发明还提供基本上不能诱导抗体依赖性细胞介导的细胞毒性(ADCC)和/或补体依赖性细胞毒性(CDC)的抗体,从而确保治疗效果主要由细胞毒性化合物的抗有丝分裂成分介导 ,而不是通过ADCC和/或CDC的间接细胞杀伤。 与增殖的非癌细胞相比,本发明的抗体还能够区分在增殖性癌细胞上更高度表达的多肽抗原。